The success of treatment using a monoclonal antibody against IL-36 receptor in generalized pustular psoriasis patients highlights the promising potential strategy of blocking the IL-36/IL-36R signaling pathway in clinical therapy (7). Here, IL1RL2 is linked to generalized pustular psoriasis.